Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Alterity Therapeutics Limited - Sponsored ADR (ATHE) vs Spero Therapeutics, Inc. (SPRO)

Alterity Therapeutics Limited - Sponsored ADR and Spero Therapeutics, Inc. are both Biotechnology companies. Alterity Therapeutics Limited - Sponsored ADR and Spero Therapeutics, Inc. are of similar size ($72.0M and $71.6M). Alterity Therapeutics Limited - Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Spero Therapeutics, Inc. trades at 8.8×. Across the 10 metrics below, Spero Therapeutics, Inc. leads on 8 and Alterity Therapeutics Limited - Sponsored ADR on 2.

Valuation

Metric ATHE SPRO Biotechnology median
P/E n/m 8.79 7.88
P/S n/m 1.17 11.47
P/B n/m 1.61 2.52
Price to free cash flow n/m 3.65 21.16
EV/EBITDA 0.94 3.41 0.74
EV/Sales n/m 0.34 10.73
Earnings yield 0.00% 11.38% (28.84%)
Free cash flow yield 0.00% 27.41% (23.03%)

Profitability

Metric ATHE SPRO Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin — 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 19.17% (57.72%)
Return on assets 0.00% 12.85% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ATHE SPRO Biotechnology median
Revenue growth (TTM) — 37.24% 5.64%
EPS growth (last fiscal year) (22.97%) 111.81% —
Revenue growth, 5-year CAGR (1.15%) 48.25% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ATHE SPRO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.52 6.12 4.73
Net debt to EBITDA 1.32 (6.38) 0.96

Dividend

Metric ATHE SPRO Biotechnology median
Dividend yield 0.61% — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ATHE SPRO Biotechnology median
Market cap 72.01m 71.63m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack